Home » Stocks » CDTX

Cidara Therapeutics, Inc. (CDTX)

Stock Price: $1.92 USD 0.00 (0.00%)
Updated Jun 24, 2021 1:23 PM EDT - Market open
Market Cap 94.01M
Revenue (ttm) 11.95M
Net Income (ttm) -75.86M
Shares Out 46.97M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $1.92
Previous Close $1.92
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.93
Day's Range 1.90 - 1.95
Day's Volume 207,445
52-Week Range 1.76 - 4.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

1 week ago - GlobeNewsWire

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

3 weeks ago - GlobeNewsWire

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -129.41% and -83.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients ...

1 month ago - GlobeNewsWire

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patient...

2 months ago - GlobeNewsWire

Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.

Other stocks mentioned: JNJ
2 months ago - Zacks Investment Research

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejec...

Other stocks mentioned: ACAD, BPTH
2 months ago - Benzinga

Cidara Therapeutics Inc (NASDAQ: CDTX) has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson & Johnson (NYSE: JNJ), to develop a...

2 months ago - Benzinga

Collaboration includes exclusive worldwide rights to Cidara's CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding

2 months ago - GlobeNewsWire

SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patient...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

3 months ago - GlobeNewsWire

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

5 months ago - GlobeNewsWire

Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara's antifungal and antiviral programs Former head of commercial API manufacturing at...

6 months ago - GlobeNewsWire

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

6 months ago - GlobeNewsWire

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

6 months ago - GlobeNewsWire

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

7 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 14.58% and -32.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

7 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections

8 months ago - GlobeNewsWire

SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patie...

9 months ago - GlobeNewsWire

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facin...

9 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -87.50% and -79.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing...

10 months ago - GlobeNewsWire

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing...

10 months ago - GlobeNewsWire

SAN DIEGO, July 17, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing...

11 months ago - GlobeNewsWire

SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing...

11 months ago - GlobeNewsWire

SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing...

1 year ago - GlobeNewsWire

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing...

1 year ago - GlobeNewsWire

SAN DIEGO and CAMBRIDGE, England, May 20, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of ca...

1 year ago - GlobeNewsWire

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -35.29% and -49.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing ...

1 year ago - GlobeNewsWire

Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020

1 year ago - GlobeNewsWire

Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -44.83% and -83.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe fungal...

1 year ago - GlobeNewsWire

SAN DIEGO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the...

1 year ago - GlobeNewsWire

SAN DIEGO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0...

1 year ago - GlobeNewsWire

No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.

Other stocks mentioned: CPE, KDMN, NEX, OVID, QEP
1 year ago - InvestorPlace

Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020

1 year ago - GlobeNewsWire

Employee feedback places Cidara among top small companies in the area Employee feedback places Cidara among top small companies in the area

1 year ago - GlobeNewsWire

SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will ...

1 year ago - GlobeNewsWire

SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Da...

1 year ago - GlobeNewsWire

Earlier this week, Cidara Therapeutics Inc. (NASDAQ: CDTX) announced a huge deal that catapulted the stock up nearly 50%.

1 year ago - 24/7 Wall Street

Cidara Therapeutics Inc (NASDAQ: CDTX) announced a development and commercialization deal Tuesday for its lead antifungal investigational drug, rezafungin.

1 year ago - Benzinga

Cidara Therapeutics Inc (NASDAQ: CDTX) shares were advancing by more than 50% Tuesday after the thinly traded, micro-cap biotech announced a development and commercialization deal for its lead medicatio...

1 year ago - Benzinga

Shares of Cidara Therapeutics Inc. CDTX, +0.00% rocketed 67% in active premarket trading Tuesday, after the biotechnology company announced a partnership with Mundipharma with a total potential value of...

1 year ago - Market Watch

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbrea... [Read more...]

Industry
Biotechnology
IPO Date
Apr 15, 2015
CEO
Jeffrey Stein
Employees
79
Stock Exchange
NASDAQ
Ticker Symbol
CDTX
Full Company Profile

Financial Performance

In 2020, CDTX's revenue was $12.07 million, a decrease of -42.30% compared to the previous year's $20.92 million. Losses were -$72.11 million, 75.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is 6.67, which is an increase of 247.40% from the latest price.

Price Target
$6.67
(247.40% upside)
Analyst Consensus: Buy